Biosimilars Versus Generics: Differences in the Regulatory Review Process

December 4, 2018

Conference | ASHP Midyear

Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discusses the regulatory review process for biosimilars and how it differs from the generic approval process.

At the American Society for Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discussed the regulatory review process for biosimilars and how it differs from the generic review process.